A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

Summary

This study is being conducted to determine how safe and how well tolerated LY3462817 is when given to participants with psoriasis. Blood tests will be done to check how much LY3462817 is in the bloodstream and how long the body takes to get rid of it. The study will last up to one year and one month for each participant. As part of protocol addendum, this study is additionally evaluating the safety and tolerability of LY3509754 in participants with psoriasis. Blood tests will be done to check how much LY3509754 is in the bloodstream and how long the body takes to get rid of it. The addendum will last up to 12 weeks for each participant.

Timeline

Start

2019-11-20

Primary completion

2022-02-09

Completion

2022-02-09

Outcome

Outcome not reported

Stopped: “Terminated due to liver findings”

Drugs

Indications